The identification of the CD34 molecule, expressed almost exclusively
on human hematopoietic stem cells and committed progenitors, and the d
evelopment of CD34-specific monoclonal antibodies have made procuremen
t of relatively pure populations of CD34(+) marrow cells for autologou
s transplantation feasible. Characterization of the immunogenicity of
CD34(+) marrow cells may facilitate the design of successful strategie
s to use these cells for allogeneic transplantation. CD34(+) marrow ce
lls from normal volunteers were enriched to greater than 98% purity by
immunoaffinity chromatography on column followed by fluorescence-acti
vated cell sorting. Purified CD34(+) cells were tested for expression
of HLA-DR and other accessory molecules, and function in hematopoietic
colony growth and mixed leukocyte culture (MLC) assays. Greater than
95% CD34(+) cells were positive for HLA-DR and 74% +/- 10% were highly
positive for CD18, the common beta-chain of a leukointegrin family. C
D34(+)/CD18(-) cells were small, agranular lymphocytes which contained
the majority of precursors for colony-forming cells detected in long-
term cultures. They produced almost no stimulation of purified T cells
from HLA-DR-incompatible individuals in bulk MLC or in limiting dilut
ion assay. In contrast. CD34(+)/CD18(+) cells were large, were enriche
d for cells forming mixed colonies in short- but not long-term assays,
and were capable of stimulating allogeneic T cells. CD86, a natural l
igand for the T-cell activation molecule CD28, was coexpressed with CD
18 in 6% +/- 3% of CD34(+) cells. CD34(+)/CD86(+) cells, but not CD34(
+)/CD86(-) cells. exhibited strong alloantigen presenting function. Th
us, pluripotent hematopoietic activity and alloantigen presenting func
tion are attributes of distinct subsets of CD34(+) marrow cells. CD34(
+)/CD18(-) or CD34(+)/CD86(-) cells may be more effective than either
the whole CD34(+) population or unseparated marrow in engrafting allog
eneic recipients and may also facilitate induction of tolerance. (C) 1
996 by The American Society of Hematology.